Galectin Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joel Lewis
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4960 Peachtree Industrial Boulevard Norcross GA United States of America 30071
- IPO Date
- Sep 4, 2002
- CIK
- 0001133416
- Website
- galectintherapeutics.com
- Similar Companies
- Business
- Galectin Therapeutics Inc. (NASDAQ: GALT) develops carbohydrate-based therapies targeting galectin proteins for the treatment of fibrosis and cancer. The company focuses on galectin-3, a protein implicated in inflammatory and fibrotic diseases, with its lead product candidate belapectin (GR-MD-02), a galectin-3 inhibitor administered intravenously in clinical development for non-alcoholic steatohepatitis (NASH) with cirrhosis and in combination therapies for hepatocellular carcinoma. Its pipeline also includes earlier-stage programs exploring galectin modulation for other fibrotic conditions and oncology indications.
Company News
Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ)
20 stocks likely to lose money even if the bull market continues
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average – Here’s What Happened
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)
Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors